Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The melanosome transfer machinery is a complex multi-protein system responsible for the movement of melanin-containing organelles (melanosomes) from melanocytes to neighboring keratinocytes in the skin and hair follicles (PMID: 33075361, 36142345). This process is essential for visible pigmentation and photoprotection, as it allows for the distribution of melanin throughout the epidermis to protect keratinocyte nuclei from UV-induced DNA damage (PMID: 25104162). The machinery involves several distinct stages: intracellular transport within melanocytes mediated by the Rab27a-Melanophilin-Myosin Va ternary complex, dendrite extension regulated by Rho GTPases like Cdc42, and intercellular transfer to keratinocytes, which is significantly regulated by the Protease-activated receptor 2 (PAR-2) (PMID: 33075361, 10702237). Dysregulation of this machinery is linked to various pigmentary disorders, including hyperpigmentation (e.g., melasma, post-inflammatory hyperpigmentation) and rare genetic conditions like Griscelli syndrome, which is caused by mutations in core components like Rab27a or Myosin Va (PMID: 11017072). Therapeutic targeting of the melanosome transfer machinery, such as through PAR-2 antagonists or agents like niacinamide that block transfer, provides a strategy for managing skin pigmentation without necessarily inhibiting the enzymatic synthesis of melanin itself (PMID: 12100180, 10702237).
Inhibition of melanosome transport within melanocytes (e.g., disruption of the Rab27a-MLPH-MyoVa complex) and suppression of melanosome uptake by keratinocytes (e.g., antagonism of PAR-2 or inhibition of phagocytosis).
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Melanosome transfer machinery.